Edition:
United Kingdom

Genocea Biosciences Inc (GNCA.OQ)

GNCA.OQ on NASDAQ Stock Exchange Global Market

0.87USD
25 Apr 2018
Change (% chg)

$-0.01 (-0.85%)
Prev Close
$0.87
Open
$0.88
Day's High
$0.88
Day's Low
$0.85
Volume
60,565
Avg. Vol
240,038
52-wk High
$7.28
52-wk Low
$0.79

Chart for

About

Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one... (more)

Overall

Beta: 1.19
Market Cap(Mil.): $66.80
Shares Outstanding(Mil.): 82.10
Dividend: --
Yield (%): --

Financials

  GNCA.OQ Industry Sector
P/E (TTM): -- 178.44 32.31
EPS (TTM): -1.98 -- --
ROI: -185.22 -0.73 12.97
ROE: -287.20 -2.77 14.84

BRIEF-Genocea Biosciences Says Jonathan Poole Delivered Resignation As CFO

* GENOCEA BIOSCIENCES - ‍ON MARCH 6, JONATHAN POOLE DELIVERED RESIGNATION AS CFO EFFECTIVE MARCH 23, 2018​

09 Mar 2018

BRIEF-Genocea Qtrly Loss Per Share $0.37

* GENOCEA REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

15 Feb 2018

BRIEF-Genocea Biosciences Entered Into Agreement With Oncovir For Manufacture & Supply Of Hiltonol

* GENOCEA BIOSCIENCES SAYS ‍ON JAN 26, CO ENTERED INTO AGREEMENT WITH ONCOVIR FOR MANUFACTURE & SUPPLY OF HILTONOL(REG) (POLY-ICLC)​ - SEC FILING Source text: (http://bit.ly/2npDhjw) Further company coverage:

31 Jan 2018

BRIEF-Bvf Partners Reports A 8.9 Pct Passive Stake In Genocea Biosciences As Of Jan 17

* BVF PARTNERS L.P. REPORTS A 8.9 PERCENT PASSIVE STAKE IN GENOCEA BIOSCIENCES INC AS OF JAN 17 - SEC FILING Source text for Eikon: (http://bit.ly/2BDcCno) Further company coverage:

29 Jan 2018

BRIEF-New Enterprise Associates 16 Reports A 39.7 Pct Stake In Genocea Biosciences As Of Jan 17

* NEW ENTERPRISE ASSOCIATES 16, L.P. REPORTS A 39.7 PERCENT STAKE IN GENOCEA BIOSCIENCES INC AS OF JAN 17 - SEC FILING Source text: (http://bit.ly/2Gm4D1B) Further company coverage:

26 Jan 2018

BRIEF-Genocea Biosciences, Inc. Announces Pricing Of $55 Mln Concurrent Public Offerings

* GENOCEA BIOSCIENCES, INC. ANNOUNCES PRICING OF $55 MILLION CONCURRENT PUBLIC OFFERINGS

17 Jan 2018

BRIEF-Genocea Biosciences Announces Proposed Concurrent Public Offerings Of Common Stock

* GENOCEA BIOSCIENCES, INC. ANNOUNCES PROPOSED CONCURRENT PUBLIC OFFERINGS OF COMMON STOCK AND CLASS A WARRANTS AND SERIES A CONVERTIBLE PREFERRED STOCK AND CLASS A WARRANTS

16 Jan 2018

BRIEF-Genocea Biosciences inc qtrly ‍loss per share $0.59​

* Genocea biosciences - ‍expects existing cash and cash equivalents sufficient to support operating expenses and capital expenditure into middle of 2018​

02 Nov 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF75.24 -0.52
Pfizer Inc. (PFE.N) $36.68 -0.38
Merck & Co., Inc. (MRK.N) $59.63 -0.46
Sanofi SA (SASY.PA) €65.87 --
AstraZeneca plc (AZN.L) 4,991.00 +1.50
GlaxoSmithKline plc (GSK.L) 1,412.20 -50.00
Vical Incorporated (VICL.OQ) $1.51 +0.01

Earnings vs. Estimates